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Abstract
Background: Information about genotypes and associated risk factors in hepatitis C virus (HCV)
infected patients in Iran is limited. The aim of this study was to identify the HCV genotypes and
associated risk factors in a group of HCV infected patients from Iran.
Results: Genotyping analysis was performed in 156 patients with positive anti-HCV and HCV-
RNA. Patients were questioned concerning documented risk factors. Genotypes 1 and 3 were
found in 87 (55.8%) and 45 (28.8%) patients, respectively. The most frequent HCV subtype was 1a
(37.8), followed by 3a (28.9%) and 1b (16.7%). There was no statistically significant difference
between the risk factors analyzed and the acquisition of HCV infection. We further found that 18
(40%) and 17 (37.8%) patients that were intravenous drug users (IVDU) had genotype 1a and 3a
respectively.
Conclusion: Genotypes 3a and 1a in Iran are less prevalent in IVDU than in Europe and USA, but
there is a high similarity between the pattern of genotype in IVDU in both Europe and United
States, and Iran. However, in this case it can not be due to people migration among countries since
history of travel abroad existed only in 6 cases (13.3%).
Background
Chronic hepatitis C infection is now recognized as an
important health problem [1]. Approximately 2–3% of
the world population is infected with hepatitis C virus
(HCV). HCV is one of the leading causes of liver failure
and cancer, and the single most common indication for
liver transplantation [2,3]. In Iran, the prevalence of HCV
infection is about 0.12% in blood donors [4], but it is
increasing. It seems that the prevalence of HCV infection
is less than 1 percent in our general population, but the
infection is emerging mostly because of problems such as
intravenous drug use and needle sharing among drug
addicts. HCV infection is the most prevalent cause of
chronic hepatitis and cirrhosis in hemophiliac [5] and
thalassemic patients [6], and patients with renal failure
[7] in Iran. Different HCV isolates worldwide show sub-
stantial nucleotide sequence variability throughout the
viral genome [8-11].
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In the present study, we used PCR analysis with type-spe-
cific primers for identification of the HVC genomic typ-
ing, which enable the separation into six major genotypes
(1 to 6) and a series of subtypes (e.g., a, b, c) [12-15].
These viral types and subtypes differ in their geographical
distribution and antigenicity [8]. Types 1, 2 and 3 are dis-
tributed almost worldwide [16-22]. Types 4, 5 and 6 have
been found in distinct geographical areas [12,20,21,23].
Interestingly, not only do the HCV genotypes seem to dif-
fer in nucleotide sequence and geographical distribution,
but there is also evidence of biological differences
between the three HCV genotypes. Patients with HCV sub-
type 1b have a poorer response to interferon alpha treat-
ment [24-27]. Mode of transmission may also affect
distribution of HCV genotypes [28-31].
Whereas the distribution of HCV genotypes in many
countries is well documented, reliable data are still miss-
ing with respect to the frequency of the different HCV gen-
otypes in Iran. We therefore conducted a study on patients
with HCV infection, and correlated the mode of transmis-
sion, and the age, sex, and liver histology with the pre-
dominance of different genotypes. Accurate knowledge of
HCV genotypes in our community is essential for success-
ful future research into vaccine development and control
strategy. Such information is needed to correctly formu-
late healthcare policies, prioritize interventions and allo-
cate resources, accordingly. The aim of our study was to
understand the main routes of transmission of HCV in
our population, chosen from a referral clinic in Tehran,
the capital of Iran.
Results
The distribution of HCV genotypes evaluated in 156
patients by genotype screening [32] showed a major prev-
alence of HCV genotype 1 in 87 (55.8%) cases. Forty-five
(28.8%) patients were infected with genotype 3, 2
patients (1.3%) with genotype 4, and 1 patient (0.6%)
had mixed infection with genotypes 1 and 3. Genotyping
was impossible in 21 patients. The distribution of sub-
types of HCV genotypes related to age, sex, source of infec-
tion, Knodell's histological activity index (HAI), status of
the liver disease, complete blood cell count (CBC), liver
function tests (LFT), fasting blood sugar (FBS), triglyceride
(TG), cholesterol, and serum protein electrophoresis
given are compared in Table 1.
The alanino aminotransferase (ALT) level was not statisti-
cally different in cases with different genotypes, although
it was slight higher in cases with genotype 4 and lower in
cases with mixed genotype
There was any significant association between subtypes of
HCV genotypes and the presence of anti-HBsAb (hepatitis
B surface antibody), anti-HBcAb (hepatitis B core anti-
body), splenomegaly, ascitis, edema, cirrhosis, grade and
stage of liver biopsy, and child score and status (inactive,
chronic, cirrhotic and active) of the disease; revealing
inexistence of any association between disease severity
(grade, stage, child score and status of the disease) and dif-
ferent genotypes.
Only one patient with mixed infection with genotype 1a
and 1b and two cases with genotype 3a had co-infection
with hepatitis B virus (P < 0.001). Only one patient with
mixed infection with genotype 1a and 1b and one case
with genotype 1b had jaundice (P < 0.001). History of
jaundice was seen more in cases with mixed infection with
genotype 1a and 1b (2, 100%), 1a (12, 20.3%), 3a (6,
13%), and 1b (3, 11.5%). Any cases with genotype 4 had
no history of jaundice.
From the 156 patients, only 135 cases had typeable geno-
types. There were 8 cases with negative HCV RNA among
21 patients with a non-typeable genotype. We were una-
ble to determine the genotype of the rest of 18 cases with
the genotype-specific primer (GSP) method. One-hun-
dred thirty patients had chronic hepatitis, either requiring
treatment (89 patients) or not (41 patients). Other 26
patients were cirrhotic and needed supportive treatment.
Duration of hepatitis for patients with both post transfu-
sion and IVDU contamination were 10.6 ± 2.75 and 8.9 ±
3.53 years, respectively.
There was not any statistical significant association
between the places of infection of the patients and geno-
type. However, genotype 4 was found only in north and
west of country and mixed infection with genotype 1a and
1b only in center. In this study, the dominant genotype(s)
in different regions of Iran consist: 1a, 1b and 3a in center
and west, 1a and 3a in north and 1a in south and east
(table 2). The geographic distribution of the patients with
a typeable genotyping is summarized in table 2.
Discussion
Genotyping is important because it provides information
as to strain variation and potential association with dis-
ease severity. In addition, it is of epidemiologic value
because it sheds light on whether prevalent HCV strains
are similar to that endemic in a certain region, such as
herein in the Middle East.
In comparison with studies made in Iran's neighbor coun-
tries, it can be understood that the most common geno-
type of Yemen, Kuwait, Iraq, and Saudi Arabia is type 4
[12]. However, subtype 1b in Turkey [33] or western bor-
der of Iran and subtype 3a in Pakistan or eastern border of
Iran are more prevalent [34]. Although genotype 4 is
found almost exclusively in Middle East and western
countries [35], this genotype is uncommon in our countryComparative Hepatology 2006, 5:4 http://www.comparative-hepatology.com/content/5/1/4
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and related to different route of contamination such as
dialysis, minor surgery, piercing or hejamat (see footnote
in Table 1), and not to transfusion, intravenous drug
abuse (IVDA) or sexual contacts. Another study showed
that genotype 4 is over-represented among hemodialysis
patients in Tehran [36]. However, we can not rule out any
definite conclusion on genotype 4 transmissions with
only 2 patients.
On the other hand, subtype 1b is more prevalent in Tur-
key and Russia [37] (west and north of Iran). This subtype
is one of the common genotypes in Iran as the present
study and some other limited studies have previously
shown [38,39]. This subtype is more frequently seen in
cases with history of hospitalization (17 cases, 60.7%),
major surgery (15 cases, 53.6%), dental surgery (12 cases,
42.9%), transfusion (11 cases, 39.3%), alcohol consump-
Table 2: The geographic distribution of the patients and their most prevalent genotypes.
Infection place N° (Percent)* Prevalent genotypes: N° (Percent)§
1a 1b 3a 4 mix
Center 77 (57.6) 33 (42.8) 15 (19.5) 27 (35.1) 0 2 (2.6)
North 18 (13.4) 7 (38.9) 2 (11.1) 8 (44.4) 1 (5.6) 0
South 1 (.7) 1 (100) 0 0 0 0
East 5 (3.7) 4 (80) 0 1 (20) 0 0
West 31 (23.1) 13 (41.9) 8 (25.8) 9 (29) 1 (3.2) 0
out of Iran 2 (1.5) 1 (50) 1 (50) 0 0 0
*Percents of cases from different geographic parts.
§Percents of the different genotypes in different geographic parts.
Table 1: Presentation of the 156 Iranian patients in relation to HCV-genotype.
Presentation of patients HCV-genotype Sig.
1a (N = 59) 1b (N = 26) 1a & 1b (N = 2) 3ac (N = 45) 4 (N = 2)
Age (years)a 37.5 ± 1.7 38.7 ± 2.4 46.5 ± 2.5 39.6 ± 1.8 46.5 ± 3.5 NSd
Male/Female (%male) 47/12 (79.7) 19/7 (73.1) 2/0 (100) 39/7 (84.8) 1/1 (50) NS
Transmission of HCV
Post-transfusional 24 (42.1) 10 (17.5) 1 (1.8) 15 (26.3) 0 NS
IVDA 18 (40) 5 (11.1) 0 18 (40) 0 NS
Sexual 16 (36.4) 6 (13.6) 0 19 (43.2) 0 NS
Hemodialysis 7 (36.8) 2 (10.5) 1 (5.3) 4 (21.1) 2 (10.5) 0.001
Hemophilia 3 (60) 0 0 2 (40) 0 NS
Thalassemia 5 (55.6) 2 (22.2) 0 1 (11.1) 0 NS
Inmate 12 (34.3) 2 (5.7) 0 17 (48.6) 0 0.041
Travel abroad 9 (40.9) 3 (13.6) 1 (4.5) 7 (31.8) 0 NS
Hejamate 8 (25) 6 (18.8) 1 (3.1) 14 (43.8) 1 (3.1) NS
Other risk factors 10 (34.5) 5 (17.2) 0 7 (24.1) 0 NS
Cirrhosis 7 507 0 N S
HAIa, b 7.8 ± 1.1 10 ± 1.3 3 ± .0 8.6 ± 1.1 12 ± .0 NS
AST (U/L) 59.9 ± 5.8 67.8 ± 9.5 48.5 ± 12.5 71.1 ± 7.5 91.5 ± 75.5 NS
ALT (U/L) 73.6 ± 7.2 94.1 ± 14.8 40 ± 5 94.7 ± 10 139.5 ± 113.5 NS
WBC (/ml) 6866 ± 501 7405 ± 578 7000 ± 500 6993 ± 366 6500 ± 500 NS
PLT (/ml) 227281 ± 20455 194560 ± 10377 314000 ± .0 217391 ± 12168 244500 ± 22500 NS
Hgb (g/dl) 14.1 ± .33 14.5 ± .42 14.2 ± 2.6 14.5 ± .32 14.4 ± 2.2 NS
FBS (mg/dl) 105.4 ± 6.8 102.7 ± 9.4 97 ± 11 102.7 ± 8 106.5 ± 1.5 NS
TG (mg/dl) 142.3 ± 11.2 123.2 ± 10.7 176 ± 110 101.1 ± 6.9 215 ± 143 .016
Cholesterol (mg/dl) 159.7 ± 6.4 173.8 ± 9.1 185 ± .0 140.8 ± 7.3 186 ± 73 NS
Serum albumin (g/dl) 3.9 ± .08 4.1 ± .13 3.6 ± .25 4.1 ± .1 - NS
Serum protein (g/dl) 7.4 ± .11 7.6 ± .18 6.4 ± .65 7.8 ± .13 - .034
Serum iron 132.6 ± 13.8 118.4 ± 18.8 - 81.1 ± 8.8 110 ± .0 .024
Weight (Kg) 71.6 ± 1.9 70.5 ± 3.4 75.5 ± 14.5 72.7 ± 1.9 84.5 ± 2.5 NS
Height (cm) 170.8 ± 1.3 167.3 ± 2.1 169.5 ± 1.5 171.8 ± 1.2 163 ± 11 NS
a Mean ± SE; b Histological activity index; c One patient had a mixed infection (3a(β)/1a); d Not significant; e A procedure in Iranian traditional 
medicine done by making shallow cuts on the trunk (upper back) and producing a suction effect that results in drawing blood from cuts (less than 
100 cc). It is usually done by a non-physician, using non-standard instruments (done for healing or cure purposes). It is also named "cupping".Comparative Hepatology 2006, 5:4 http://www.comparative-hepatology.com/content/5/1/4
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tion and minor surgery (each one in 8 cases, 28.6%),
whereas making 16.7% as a total.
Although the previous studies have had lower sample
sizes, their results are similar to our study. They had con-
cluded that subtypes 1a, 3a, and 1b are the most common
types respectively and that type 4 is rare [38,39].
A similarity was observed between our country and both
Pakistan (the eastern neighbor of Iran) and India, in
which the genotype 3 is very prevalent and genotype 2 is
very rare, like in our country [40,41]. Other studies in Iran
have shown the absence of genotype 2 as well [36,38,42].
We think that this can be due to the high rate of immigra-
tion from these countries to Iran, especially when consid-
ering the fact that the prevalence of HCV infection in these
countries is higher than Iran. However, more investiga-
tions are needed for establishing a definitive judgment.
Genotypes 3a and 1a are more prevalent in IVDU in
Europe and USA [28-31,43]. In the present study, 18
(40%) and 17 (37.8%) patients with IVDA had genotype
1a and 3a respectively. It seems that there is a high simi-
larity between the pattern of genotype in IVDU in Europe
and United States when compared with Iran. However, it
can not be due to migration of these people to these coun-
tries because the history of travel abroad was only seen in
6 cases (13.3%).
In the present study, and concerning the route of HCV
transmission, most of the patients seem to have multiple
routes of contamination which limits the conclusion on
relationship between genotype and route of contamina-
tion. The inmate route of contamination may be due to
IVDA, as it is observed in other countries. However, geno-
type 3 was more frequent in IVDU. Genotype 4 was also
seen only in patients undergoing hemodialysis and/or
hejamat.
There was no difference in genotypes in terms of age and
sex of the patients. This pattern is different when com-
pared to reports from developed countries, where life-
styles among young adults seem to have influenced the
molecular epidemiology of HCV by the introduction of
subtype 1a and 3a from USA and Southeast Asia into their
young drug addicts [44].
Our results are in accordance with the predominance of
genotype 1 observed in most countries worldwide
[12,16,20,45,46]. With respect to the zero frequency of
genotype 2, our data differ from those published for
patients in the United States, Europe, and even Asia,
which showed a different prevalence of genotype 2
[19,24,31,35,47].
Conclusion
Genotypes 3a and 1a in Iran are less prevalent in IVDU
when compared with Europe and USA. Moreover, it seems
that there is a high similarity between the pattern of gen-
otype in IVDU in Iran when compared with those in
Europe and United States. However, we think that this
occurrence can not be due to migration phenomena
among involved countries because of history of travel
abroad existed only in 6 cases (13.3%).
Materials and methods
We evaluated all the 156 cases with hepatitis C infection
(125 male, 31 female; mean age 38.9 ± 1, age range 14–
71 years) referred to the Tehran Hepatitis Center from
June 2002 to May 2003, consecutively. The diagnosis of
chronic hepatitis C was made on the basis of the presence
of anti-HCV antibodies in both sera detected by third-gen-
eration commercially available enzyme-linked immuno-
surbent assay (ELISA) kits (ETI HCV K-3, DiaSorin, Spain)
and HCV RNA detected qualitatively by reverse tran-
scriptase polymerase chain reaction (Amplicore II, Roche,
NJ, USA).
CBC, LFT and serum protein electrophoresis were per-
formed, and FBS, TG, and also cholesterol were checked in
all patients. These were questioned concerning docu-
mented risk factors acting as main infection routes,
namely IVDA, blood transfusions, acupuncture or tattoos,
extra marital sexual contact, hemodialysis, hemophilia,
thalassemia. Other risk factors were also checked.
At the time of the study 89 patients had chronic hepatitis
requiring antiviral therapy. Twenty-six cases were cirrhotic
and 41 patients did not need treatment. Liver biopsy was
performed in 72 patients. Chronic hepatitis was diag-
nosed in 57 and liver cirrhosis in 12 patients. No specific
pathologic change occurred in only 3 patients. The histo-
logical finding was further graded according to the HAI of
Knodell et al. [34]. The mean HAI score was 8.7 ± 0.6
(range 1–20).
The mean ± standard error (SE) was used for the descrip-
tion of quantitative variables. Whereas the Student t-test
and one-way ANOVA were used for comparing quantita-
tive variables, the chi-square test was used for compari-
sons involving categorical variables. Differences or
correlations with P < 0.05 were considered statistically sig-
nificant. SPSS software (Version 11.5, SPSS Inc. Chicago,
Illinois, USA) was used for the analysis. The study proto-
col conforms to the ethical guidelines of the 1975 Decla-
ration of Helsinki.
For the genotype specific primer approach, viral RNA was
extracted from 100 μl of HCV positive patients' serum,
using guanidine throcyanate and isopropanol. Precipi-Comparative Hepatology 2006, 5:4 http://www.comparative-hepatology.com/content/5/1/4
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tated RNA was washed with 70% ethanol and then dis-
solved in 200 μl TE buffer. Five μl of the dissolved RNA
was immediately reverse transcribed by using random
hexamer. Genotyping was performed as described previ-
ously [32].
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